DexCom Inc. Stock Outperforms Market On Strong Trading Day

RE Royalties Ltd

Change company Symbol lookup

Select an option...

RROYF RE Royalties Ltd

CHWY Chewy Inc

AATV Adaptive Ad Systems Inc

MSGS Madison Square Garden Sports Corp

BST BlackRock Science and Technology Trust

ETSY ETSY Inc

SPCE Virgin Galactic Holdings Inc

XNXNX Nuveen New York Select Tax Free Income Portfolio

$NQUSM55102010EURT Nasdaq US Mid Cap Iron and Steel Tot

WPC WP Carey Inc

Utilities : Independent Power & Renewable Electricity Producers | Small Cap Blend
Based in Canada

Company profile

RE Royalties Ltd. is a Canada-based company, which is primarily engaged in the acquisition of revenue-based royalties from renewable energy generation facilities and other clean energy technologies. The Company provides non-dilutive royalty financing solutions to privately held and publicly traded renewable energy generation and development companies and clean energy technology companies. It provides financing solutions for its clients when traditional financing options are not available or suitable. It has ownership of royalties from renewable energy projects in Canada, the United States, and Europe. Its diversified portfolio includes solar parks, wind farms, and run of the river hydro facilities. The Company owns approximately 104 royalties on solar, wind, hydro, battery storage, and renewable natural gas projects in Canada, Europe, and the United States. The Company's wholly owned subsidiary is RE Royalties (Canada) Ltd.

DexCom Inc. Stock Outperforms Market On Strong Trading Day

4:50 pm ET January 24, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of DexCom Inc. (DXCM) advanced 1.12% to $426.83 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.28% to 4,410.13 and the Dow Jones Industrial Average rising 0.29% to 34,364.50. The stock's rise snapped a two-day losing streak. DexCom Inc. closed $232.62 below its 52-week high ($659.45), which the company achieved on November 18th.

The stock outperformed some of its competitors Monday, as Johnson & Johnson (JNJ) fell 1.15% to $162.97, Abbott Laboratories (ABT) fell 1.60% to $123.82, and Medtronic PLC (MDT) fell 1.32% to $104.21. Trading volume (1.2 M) eclipsed its 50-day average volume of 824,007.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 24, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 24, 2022 16:50 ET (21:50 GMT)